BRAF V600E mutation as a resistance mechanism to osimertinib has been identified in 3% of NSCLC patients positive for EGFR mutations, irrelevant of the presence of a T790M mutation (25, 29, 86). Here, BRAF is linked to non-small cell lung carcinoma.